New eye drop trial offers hope for chronic dry eye sufferers
NCT ID NCT07224529
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a prescription eye drop called Vevye (cyclosporine 0.1%) in 48 adults with meibomian gland dysfunction (MGD), a common cause of dry, burning eyes. Participants use the drops twice daily for 24 weeks, and researchers measure changes in eye symptoms, gland function, and eye surface health. The goal is to see if Vevye can improve both symptoms and signs of MGD, potentially offering a new treatment option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEIBOMIAN GLAND DYSFUNCTION (MGD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham, School of Optometry, Clinical Eye Research Facility
RECRUITINGBirmingham, Alabama, 35294, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.